ROE
-4.2%
ROE -4.2% is below the quality threshold; compare the multi-year trend before calling it structural.
NASDAQ · Utilities · Small Cap · Mkt cap $23.4B · Vol 10.38M
$20.45
▼ -1.92% today
Live · market · updated 10:07:35 PM
Day $20.41–$20.68 · 52w $10.15–$21.20
Research Viatris Inc. (NASDAQ: VTRS) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Source: Yahoo Finance — Viatris Inc. company profileCompany website
Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.
Weighted 13-factor score / 100
Viatris Inc. scores 48/100 on the DeepScreen quality-and-value model. Growth is running near -0.3% with a PEG of 3.77, ROCE of 1.3% and debt/equity at 0.99x. Quality and price roughly offset each other; wait for a better entry or clearer growth.
Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Target price, trim level & stop-loss is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
The 48/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.
Cheap vs. earnings. Weighted contribution: 7.8 points.
Low multiple. Weighted contribution: 9.4 points.
Good upside gearing. Weighted contribution: 4.6 points.
Modest sales multiple. Weighted contribution: 5.2 points.
Below cost of capital risk. Weighted contribution: 0.6 points.
Weak. Weighted contribution: 0.5 points.
Overvalued vs. growth. Weighted contribution: 0.6 points.
Red flag — paying out more than it earns. Weighted contribution: 0.4 points.
Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.
Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.
Provider-reported period-over-period growth
Provider-reported period-over-period growth
Return on equity
Return on capital employed
Net income as a share of revenue
Debt relative to shareholder equity
127% of operating cash flow
Cash $2.01B · Debt $13.58B
Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.
Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.
The model sees a 960% payout ratio. Check dividend funding against earnings and free cash flow.
Free cash flow is 127% of operating cash flow in the latest provider snapshot.
Signals are intended to highlight questions for research, not replace company filings or independent review.
Industry match: Drug Manufacturers - Specialty & Generic. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.
Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.
DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
4/84
4 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
High manipulation risk-4.09
Accrual-quality check only: operating cash flow is -409% of reported net profit. Below 80% means profits aren't fully backed by cash.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
P/E Ratio (TTM)
Modeled7.4x
Cheap vs. earnings
Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.
PEG Ratio
LivePro
Advanced ratio · DeepScreen Pro
Pro
P/S Ratio
Live1.59x
Modest sales multiple
Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.
P/B Ratio
Live1.71x
Reasonable
Price versus net asset value on the balance sheet. Most meaningful for banks, NBFCs and asset-heavy businesses (manufacturing, real estate) where book value closely tracks real worth.
EV/Revenue
LivePro
Advanced ratio · DeepScreen Pro
Pro
EV/EBITDA
LivePro
Advanced ratio · DeepScreen Pro
Pro
ROE
Live-4.2%
Weak
Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.
ROA
Live2.9%
Asset-heavy / inefficient
Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.
ROCE
Modeled1.3%
Below cost of capital risk
Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.
Debt / Equity
Live0.99x
Manageable
Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.
LT Debt / Equity
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
Payout Ratio
Live960%
Red flag — paying out more than it earns
Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.
Operating Leverage
Modeled2.17x
Good upside gearing
How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.
DCF & Graham intrinsic value calculators is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.
Loading live headlines…
Review the scoring factors, underlying data and limitations before comparing companies.
Read the methodology